Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 13, 2016 - Issue 7
Submit an article Journal homepage
362
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study

Alessandra LugaresiDepartment of Neuroscience, Imaging and Clinical Sciences, G. ‘d’Annunzio University’ - S.S. Annunziata Hospital, Chieti, ItalyCorrespondence[email protected]
,
Francesca De RobertisDepartment of Neurology, AUSL ‘Vito Fazzi’, Lecce, Italy
,
Marinella ClericoDivision of Neurology, Department of Clinical and Biological Science, S. ‘Luigi Gonzaga’ Hospital, University of Turin, Orbassano, Italy
,
Vincenzo Brescia MorraDepartment of Neurological Science, ‘Federico II’ University, Naples, Italy
,
Diego CentonzeDepartment of Neuroscience, Tor Vergata University, Rome & IRCCS Neuromed, Pozzilli, IS, Italy
,
Stefano BorghesanMedical Affairs Department Merck Serono, Rome, Italy
,
Giorgia Teresa ManiscalcoNeurology Clinic, Antonio Cardarelli Hospital, Naples, Italy
& on behalf of the RIVER study group show all
Pages 931-935 | Received 10 May 2015, Accepted 26 Jan 2016, Published online: 24 Feb 2016

References

  • Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014;122:231–266. doi:10.1016/B978-0-444-52001-2.00010-8.
  • Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9:409–416.
  • Weinstock-Guttman B. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Am J Manag Care. 2013;19(17 Suppl):s343–54.
  • Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int. 2014;2014:262350.
  • Marta M, Giovannoni G. Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. CNS Neurol Disord Drug Targets. 2012;11:610–623.
  • Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opin Pharmacother. 2006;7(Suppl 1):S1–9.
  • Visser LH, Van Der Zande A. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis. Eur J Neurol. 2011;18:1343–1349.
  • Grytten N, Aarseth JH, Espeset K, et al. Stoppers and non-starters of disease-modifying treatment in multiple sclerosis. Acta Neurol Scand. 2013;127:133–140.
  • Tremlett H, Van Der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17:565–576.
  • Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10:225.
  • Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. 2014;14:1029–1042.
  • Heesen C, Bruce J, Feys P, et al. Adherence in multiple sclerosis (ADAMS): Classification, relevance, and research needs. A meeting report. Mult Scler. 2014;20:1795–1798.
  • Remington G, Rodriguez Y, Logan D, et al. Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care. 2013;15:36–45.
  • Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1–9.
  • D’Arcy C, Thomas D, Stoneman D, et al. Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence. 2012;6:55–61.
  • Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol. 2012;12:7.
  • Devonshire VA. Verdun di Cantogno E. Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis. Ther Deliv. 2011;2:1455–1465.
  • Lugaresi A. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv. 2013;10:273–283.
  • Willis H, Webster J, Larkin AM, et al. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device. Patient Prefer Adherence. 2014;8:843–851.
  • Johnson JR, Lossignol D, Burnell-Nugent M, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46:207–218.
  • Lugaresi A, Ziemssen T, Oreja-Guevara C, et al. Improving patient-physician dialog: commentary on the results of the MS Choices survey. Patient Prefer Adherence. 2012;6:143–152.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.